InflaRx N.V. (NASDAQ:IFRX – Free Report) – Equities research analysts at HC Wainwright issued their Q3 2026 earnings per share estimates for shares of InflaRx in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst M. Keller expects that the company will post earnings per share of ($0.09) for the quarter. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for InflaRx’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for InflaRx’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.35) EPS, FY2027 earnings at ($0.36) EPS and FY2028 earnings at ($0.38) EPS.
A number of other equities analysts also recently weighed in on the stock. Zacks Research raised shares of InflaRx from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 27th. Cantor Fitzgerald increased their target price on InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday. Wall Street Zen upgraded InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Raymond James Financial raised InflaRx from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $7.00 to $9.00 in a research report on Wednesday, May 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.
InflaRx Stock Performance
IFRX opened at $1.96 on Monday. InflaRx has a 1 year low of $0.78 and a 1 year high of $2.95. The company’s 50 day simple moving average is $1.89 and its 200 day simple moving average is $1.54. The stock has a market capitalization of $141.69 million, a PE ratio of -3.38 and a beta of 2.48.
InflaRx (NASDAQ:IFRX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.04).
Institutional Trading of InflaRx
A number of hedge funds and other institutional investors have recently modified their holdings of IFRX. Bank of America Corp DE acquired a new stake in InflaRx during the 3rd quarter valued at approximately $3,316,000. Suvretta Capital Management LLC increased its holdings in InflaRx by 22.4% during the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock worth $8,013,000 after purchasing an additional 1,450,000 shares during the last quarter. 683 Capital Management LLC raised its position in shares of InflaRx by 47.3% in the 4th quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock valued at $3,348,000 after purchasing an additional 1,065,000 shares in the last quarter. Woodline Partners LP acquired a new position in shares of InflaRx in the 1st quarter valued at approximately $766,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of InflaRx in the 2nd quarter valued at approximately $262,000. 42.39% of the stock is owned by hedge funds and other institutional investors.
InflaRx Company Profile
InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.
Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.
Read More
- Five stocks we like better than InflaRx
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.
